[Insightec in PR Newswire] Insightec announces milestone of first patients enrolled in the pivotal LIBERATE clinical trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors)
HAIFA, Israel & MIAMI, Dec. 15, 2022 /PRNewswire/ — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, announced today the first patients have enrolled in the pivotal LIBERATE clinical trial (Liquid Biopsy with Low Intensity Ultrasound in Brain Tumors). Enrollment in LIBERATE marks the start of an international effort to assess safety and efficacy of using Insightec’s focused ultrasound (FUS) platform to temporarily disrupt the blood brain barrier (BBB) to enable liquid biopsies in patients with glioblastoma, the most common primary malignant brain tumor in adults. Read...
Read More